InsBio

INS Bioscience Berhad, commonly known as INSBio, was a Malaysian biotechnology company focused on the research, development, and commercialization of herbal medicines and dietary supplements. The company gained prominence for its work in "plant insulin" and its flagship product, Insupro Forte, which was marketed for the management of diabetes. INSBio operated through several subsidiaries, including INS Enterprise and INS Bioscience, and was listed on the MESDAQ market of Bursa Malaysia. Despite its early success and international recognition for its herbal innovations, the company faced financial difficulties and was eventually delisted in 2014.